Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations

The RAS–RAF–MEK–ERK signaling cascade is among the most frequently mutated pathways in human cancer. Approximately 50% of melanoma patients possess a druggable hotspot V600E/K mutation in the BRAF protein kinase. FDA-approved combination therapies of BRAF and MEK inhibitors are available that provid...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Oncogene 2018-06, Vol.37 (24), p.3183-3199
Hauptverfasser:	Dankner, Matthew, Rose, April A. N., Rajkumar, Shivshankari, Siegel, Peter M., Watson, Ian R.
Format:	Artikel
Sprache:	eng
Schlagworte:	45/23 631/208/68 631/67/1059/602 64/60 96 Amino acids Antineoplastic Agents - pharmacology Apoptosis Cancer Carcinoma, Non-Small-Cell Lung - genetics Carcinoma, Non-Small-Cell Lung - mortality Care and treatment Cell Biology Cellular signal transduction Colorectal cancer Colorectal carcinoma Colorectal Neoplasms - drug therapy Colorectal Neoplasms - genetics Drug development Extracellular signal-regulated kinase Gene mutations Genetic aspects Genetic research Health aspects Human Genetics Humans Identification and classification Internal Medicine Kinases Lung cancer Lung Neoplasms - genetics Lung Neoplasms - mortality MAP kinase MAP Kinase Signaling System - drug effects Medicine Medicine & Public Health MEK inhibitors Melanoma Melanoma - genetics Melanoma - mortality Molecular Targeted Therapy - methods Monomers Mutation Neoplasms - drug therapy Neoplasms - genetics Non-small cell lung carcinoma Oncology Patients Protein Domains Protein kinase Protein Kinase Inhibitors - pharmacology Protein kinases Proto-Oncogene Proteins B-raf - antagonists & inhibitors Proto-Oncogene Proteins B-raf - chemistry Proto-Oncogene Proteins B-raf - genetics Raf protein Ras protein Review Article Signal transduction Tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!